Core Viewpoint - SELLAS Life Sciences Group, Inc. has announced the immediate exercise of existing warrants, resulting in gross cash proceeds of approximately $31.0 million for the purchase of up to 22,363,714 shares of common stock [1][2]. Group 1: Financial Transaction - The immediate exercise of the existing warrants will provide the company with gross cash proceeds of about $31.0 million [1]. - Investors exercising the existing warrants will receive new registered warrants to purchase the same number of shares at an exercise price of $2.00, which will be exercisable immediately and will expire five years from issuance [2]. - The transaction is expected to close on or about October 28, 2025, pending customary closing conditions [2]. Group 2: Advisory and Registration - A.G.P./Alliance Global Partners and Maxim Group LLC acted as financial advisors for this transaction [3]. - The offering is being made under an effective shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission [4]. Group 3: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [7]. - The company's lead product candidate, GPS, targets the WT1 protein and has potential applications in treating a wide range of hematologic malignancies and solid tumors [7]. - SELLAS is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which has shown a high response rate in AML patients with unfavorable prognostic factors [7]. Group 4: Upcoming Events - SELLAS will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders and company management to discuss the treatment landscape for acute myeloid leukemia [5].